Home » Stocks » SLN

Silence Therapeutics PLC (SLN)

Stock Price: $25.39 USD 0.00 (0.00%)
Updated May 12, 2021 4:00 PM EDT - Market open
Market Cap 776.24M
Revenue (ttm) 5.48M
Net Income (ttm) -32.55M
Shares Out 29.80M
EPS (ttm) -1.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 12
Last Price $25.39
Previous Close $25.39
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 25.39 - 25.39
Day's Volume 139
52-Week Range 15.00 - 28.06

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Silence Therapeutics to Participate in Fireside Chat at the RBC Capital Markets Global Healthcare Conference

1 day ago - GlobeNewsWire

Silence Therapeutics PLC (LON:SLN, NASDAQ:SLN) has begun treating the first patient in the phase I study of its lead asset. SLN124 is being developed for the treatment of types of anaemia, the blood dis...

2 weeks ago - Proactive Investors

Silence Therapeutics PLC (LON:SLN, NASDAQ:SLN) said had received a further US$2mln from commercial partner Mallinckrodt under a deal potentially worth up to US$2bn in milestones and royalties. In 2019, ...

Other stocks mentioned: MNKKQ
2 weeks ago - Proactive Investors

Silence Therapeutics Announces Publication in Cardiovascular Research Highlighting the Emerging Potential of RNA Therapeutics in Preventing Lipoprotein(a)-Mediated Cardiovascular Disease

4 weeks ago - GlobeNewsWire

Silence Therapeutics PLC (LON:SLN, NASDAQ:SLN) said its medics and scientist has contributed to a peer-reviewed paper that explores the “promising potential” RNA interference (RNAi) therapies for treati...

4 weeks ago - Proactive Investors

Silence Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

1 month ago - GlobeNewsWire

Silence Therapeutics Reports Full-year 2020 Results Advancing clinical programmes; On-track for three phase 1 data readouts in 2021

1 month ago - GlobeNewsWire

What does Silence do? The name of Silence Therapeutics PLC (LON: SLN, NASDAQ: SLN) provides a hint as to what it does.

1 month ago - Proactive Investors

Silence Therapeutics PLC (LON:SLN) is cashed up and ready to pick up the pace in 2021 after a transformational 2020, it told investors. Cash and cash equivalents at the end of 2020, the company had cash...

1 month ago - Proactive Investors

Silence Therapeutics PLC (LON:SLN, NASDAQ:SLN) said it will receive US$2mln following the start of work on a third drug target as part of its research collaboration with Mallinckrodt. The two are focuse...

Other stocks mentioned: MNKKQ
2 months ago - Proactive Investors

Silence Therapeutics PLC (LON:SLN, NASDAQ:SLN) said it has begun dosing patients with SLN360, a putative treatment for elevated Lipoprotein (a), ‘bad' cholesterol associated with increased risk of heart...

2 months ago - Proactive Investors

What does Silence do? The name of Silence Therapeutics PLC (LON: SLN, NASDAQ: SLN) provides a hint as to what it does.

3 months ago - Proactive Investors

Iconic Labs PLC (LON:ICON), a multidivisional new media and technology business, announced that it has appointed Sarah Dees as its chief executive officer and an executive director with immediate effect...

Other stocks mentioned: TLSA
3 months ago - Proactive Investors

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION...

3 months ago - GlobeNewsWire

Silence Therapeutics Appoints Michael H. Davidson, MD, to Board of Directors

4 months ago - GlobeNewsWire

Silence Therapeutics Appoints Craig Tooman as Chief Financial Officer

4 months ago - GlobeNewsWire

Silence Therapeutics to Participate in January Virtual U.S. Investor Conferences

4 months ago - GlobeNewsWire

About SLN

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-as... [Read more...]

Industry
Biotechnology
CEO
David Solomon
Employees
65
Stock Exchange
NASDAQ
Ticker Symbol
SLN
Full Company Profile

Financial Performance

In 2020, SLN's revenue was $5.48 million, an increase of 2,145.49% compared to the previous year's $244,000. Losses were -$32.55 million, 66.2% more than in 2019.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for SLN stock is "Strong Buy" and the 12-month stock price forecast is 2,301.66.

Price Target
$2,301.66
Analyst Consensus: Strong Buy